Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871961 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient
A Phase 1 study, sponsored by medac.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT01871961 is a Phase 1 study that has completed, run by medac. The registered enrollment target is 105 participants.
The verdict
NCT01871961, a Phase 1 study, has completed, sponsored by medac.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).
Interventions
- DRUG Methotrexate (Metoject® prefilled pen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01871961
The ClinicalTrials.gov registry entry for NCT01871961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is medac, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methotrexate (Metoject® prefilled pen) is the first listed.
NCT01871961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01871961 about?
NCT01871961 is a clinical study titled "Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient". To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).
What is the current status of trial NCT01871961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2012-10. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01871961?
The interventions under investigation include: Methotrexate (Metoject® prefilled pen) (DRUG).
Who is sponsoring clinical trial NCT01871961?
This trial is sponsored by medac, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.